A phase III, adjuvant trial comparing three chemotherpay regiments in women with node-positive breast cancer: Docetaxel/Doxorubicin/Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/Cyclophosphamide followed by DD. Paclitaxel; (DD AC followed by DD P)